Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin for psychotherapists and its effect on patient-perceived therapist responsiveness
MOH_2024-03-28_013316Phase 2Not yet recruiting
- Sponsor
- פרופ דנה צור ביתן
- Start
- May 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial in mental disorder comparing Intranasal oxytocin with Intranasal placebo (2 arms). Primary endpoints: Patient-perceived therapist empathy, Patient-perceived therapist attentiveness and responsiveness and 1 more. Planned start May 2024; status: not yet recruiting.
02
Drugs
oxytocin
03
Conditions
mental disorder
Beyond the preview
Go deeper on MOH_2024-03-28_013316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-03-28_013316.